Cardiovascular Genetic Medicine: The Genetics of Coronary Heart Disease by unknown
Cardiovascular Genetic Medicine: The Genetics of Coronary
Heart Disease
David Seo & Pascal J. Goldschmidt-Clermont
Received: 20 March 2008 /Accepted: 23 April 2008 /Published online: 23 May 2008
# The Author(s) 2008
Abstract Advances in genomic technologies have provided
researchers with an unprecedented opportunity to identify
genes that may contribute to the development of coronary
heart disease. The power of these technologies lies in their
ability to survey the entire genome in a nonbiased fashion
to find genes and gene variants associated with coronary
heart disease. This article reviews different genomic
approaches for studying coronary heart disease and the
clinical implications of using genetic information.
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Introduction
According to the latest statistics from the American Heart
Association, over 650,000 people in the United States died
as the result of atherosclerotic coronary heart disease (CHD)
events such as myocardial infarctions (MI) [1]. Additionally,
for a substantial number of individuals, sudden death or
nonfatal MI were their first manifestation of CHD and
occurred without warning. Therefore, considerable efforts
have gone toward improving diagnostic and prognostic
tools and developing more effective treatment strategies.
A new line of research has been to define the genetic
component of this disease. Many believe that knowledge of
the genes contributing to disease development and progres-
sion will provide new opportunities for stratifying people
by their individual disease risk, identifying novel therapeu-
tic targets, and tailoring management strategies based on
inherent genetic characteristics [2–4]. Thus far, the effort to
pinpoint the genetic component of CHD has been difficult
owing to the complex nature of the disease, but the
application of new genomic methods provides hope of
ultimate success. The objective of this article is to provide
an overview of the current knowledge regarding the
genetics of CHD and the possible clinical implications of
the genetic information.
Background
Atherosclerotic CHD results from the interaction between
an individual’s genetic make up and environmental factors
such as smoking and diet [3, 5]. There are rare Mendelian
disorders for which single gene changes lead to accelerated
atherosclerosis such as familial hypercholesterolemia. In the
more common “garden variety” atherosclerosis, however,
multiple genes are likely to influence the disease process by
enhancing disease susceptibility or by augmenting the
impact of environmental risk factors. The genetic compo-
nent is likely to be multigenic and comprised of a collection
of gene variants such as single nucleotide polymorphisms
(SNPs). Each individual SNP may have a modest effect on
the quantity or function of a translated protein product.
However, when individual SNPs are aggregated, the
combination of the multiple variants may have a major
impact on disease biology. In addition, it is important to
consider the interaction between genes and gene variants
with environmental risk factors. For instance, a particular
combination of SNPs may lead to increased disease
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susceptibility in one setting of environmental risk factors
but may decrease disease susceptibility in another setting
[6]. In such a multigenic disease model, identifying the
gene variants associated with atherosclerosis development
and progression could be valuable disease biomarkers new
diagnostic and prognostic tools. Some of the gene variants
may be functional biomarkers that can be used to assess
treatment response or serve as targets for novel treatment
strategies. The obvious challenge is how one identifies the
genes and gene variants that collectively contribute to
coronary atherosclerosis. With the advent of broad-based
genomic technologies, researchers now have tools for
studying the genetic component of multigenic disorders
like CHD. What follows is a brief overview of three types
of high throughput genomic methods that are well suited
for studying CHD and their results compiled to date.
Genomic Studies of Coronary Heart Disease
Linkage Analysis
Linkage analysis is a nonbiased and powerful approach for
identifying causative genes for complex diseases [7]. The
analysis is conducted without a priori identification of
potential candidate genes or their chromosomal locations.
Linkage analysis looks for DNA markers that cosegregate
with the disease phenotype between affected family
members at a rate that is statistically greater than random
chance. The chromosomal region containing the DNA
markers can, then, be examined in further detail to look
for potential candidate genes. This methodology has
successfully defined the etiology for many monogenic
disorders by studying families with a high prevalence of
premature atherosclerotic disease. There have been several
successful such studies in CHD. One study by Wang et al.
examined a family cohort with a high prevalence of
myocardial infarction and found linkage for a region on
chromosome 15. [8] The putative candidate gene in this
chromosomal region was identified as myocyte enhancer
factor 2A (mef2a). In another linkage study, Broeckel et al.
studied a group of 513 unrelated families in which there
was at least one member with a documented myocardial
infarction. [9]. In this study, a region on chromosome 14
was linked to the myocardial infarction event; however, the
putative causative gene(s) could not be identified further.
Another linkage study performed by the Genetics of Early
Onset Coronary Artery Diseases (GENECARD) investiga-
tors looked at families with early-onset coronary artery
disease [10]. In this study, researchers found multiple
linked regions on chromosomes 1, 3, 5, 7, and 19, and
recently, the GENECARD investigators have identified
putative candidate genes within the chromosome 3 regions:
the GATA2 transcription factor [11], limbic system-associ-
ated membrane protein [12], and Kalirin [13] genes—all of
which had never been previously associated with athero-
sclerosis or CHD.
In considering the three linkage studies discussed, there
is a notable lack of agreement in the results. One
explanation may be the significant differences in the subject
groups and the outcome variable analyzed by each study.
Wang et al. performed their analyses for CHD genes in a
single family cohort while Broeckel et al. and the
GENECARD investigators used hundreds of unrelated
families. This may explain why mef2a was not found in
the other two studies given the focus on a single family,
albeit a large cohort. The major findings from Broeckel et
al. and the GENECARD investigators were also quite
different, possibly due to differences in the populations and
phenotypes studied. The probands in the Broeckel study
had a confirmed diagnosis of myocardial infarction.
Additional affected family members defined as those with
a diagnosis of myocardial infarction or history of revascu-
larization by coronary artery bypass surgery or percutane-
ous intervention. The GENECARD study included a much
wider range of study subjects. Affected subjects were
defined as those with myocardial infarction, unstable
angina, coronary atherosclerosis diagnosed by stress test
or cardiac catheterization, and individuals with a docu-
mented history of disease or revascularization. So, the
population was much broader than the Broeckel study. In
addition to differences in the subject groups, the phenotype
of interest was different. The investigators in the Broeckel
study looked for genes linked to myocardial infarction while
the GENECARD investigators identified genes linked to the
incidence of early onset coronary artery disease.
Whole Genome Association
In the past, genetic association studies examined a limited,
defined number of polymorphisms within a handful of
candidate genes for association with a disease phenotype or
outcome. While valuable, the need to preselect these
polymorphisms was the main limitation of this methodol-
ogy. However, using the latest genomic technologies,
researchers can now assay hundreds of thousands of SNPs
simultaneously in a single individual using “SNP chips”.
High throughput genotyping using SNP chips with subject
cohorts containing thousands of individuals has made it
possible to perform genetic association studies in a non-
biased fashion [14–16]. There have been two recent studies
that performed whole genome association to identify SNPs
associated with the development of myocardial infarctions
[17, 18]. Both were large case-control studies of thousands
of subjects. Using SNP chips, McPherson et al. and
Helgadottir et al. found three different SNPs (rs10757278
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in Helgadottir and rs10757274 and rs2383206 in McPher-
son) on chromosome 9p21 adjacent to the tumor suppressor
genes, CDKN2A and CDKN2B, which were highly associ-
ated with myocardial infarction. These three SNPs are not
located within a known or putative gene, and their
functional roles, if any, have not been determined.
However, the SNPs may indeed be true biomarkers for
myocardial infarction risk as they have been validated by
other independent studies [17, 18]. Approximately 20% of
Caucasians carry copies of the SNPs, and the lifetime risk
of myocardial infarction for homozygous carriers of the
SNPs is over 20%. A clinical genetic test evaluating these
SNPs is now commercially available.
Other ongoing whole genome association studies for
CHD include the Women’s Genomic Health Study and the
Cardiogenics Project which may confirm and identify new
SNPs associated with cardiovascular disease.
Gene Expression Profiling
The use of functional genomics is another approach to
identify genes and pathways that contribute to the devel-
opment and progression of coronary atherosclerosis [2, 19].
This approach analyzes disease in relevant tissues to look
for changes in the abundance of transcribed genes or
messenger RNAs (mRNA) that correlate with a disease
state, clinical outcome, or therapeutic response. Functional
genomics quantifies the levels of tens of thousands of
mRNAs simultaneously to identify genes with significant
differential expression. There have been several large
studies of human atherosclerosis to date using gene
expression analysis. In one study, Seo et. al. performed
gene expression analysis on human aortic tissues collected
at the time of organ donation to identify genes associated
with the degree of atherosclerotic burden [20]. By compar-
ing aortic tissues with minimal or severe disease, research-
ers found a number of differentially expressed genes. The
candidate genes included many that were previously
associated with atherosclerosis as well as a number of
novel genes. Another study by Randi et al. performed gene
expression analysis of atherosclerotic plaques obtained by
atherectomy from patients with stable and unstable coro-
nary artery disease [21]. Analysis revealed differential
expression of genes known to be involved in hemostasis
and inflammation such as protein S (PROS1), cyclo-
oxygenase 1 (COX1), and interleukin 7 (IL7). Another
unique study examined gene expression in the peripheral
blood mononuclear cells of patients with and without
significant carotid atherosclerosis [22]. They found differ-
ential expression in a number of regulatory genes and
transcription factors including Finkel–Biskis–Jinkins oste-
osarcoma protooncogene and dual specificity phosphatase
1. An intriguing implication of this study result is the
possibility that blood gene expression could be used as a
molecular signature to detect the presence of atherosclerosis.
Clinical Implications of Genetic Information
Clearly, recent research has generated interesting new
information regarding genes that are associated with
coronary atherosclerosis and the development of CHD
events, particularly myocardial infarctions. The key question
at this point is how to bring these results to clinical practice.
One way to apply new genetic information is the
development of new diagnostic and prognostic tests for
CHD. As reviewed elsewhere (Hershberger review in this
journal issue), genetic information is already being used
clinically for single gene disorders such as channelopathies
[23, 24] and Familial Hypercholesterolemia [25, 26]. There
is also a growing number of clinical genetic tests for
nonMendelian settings such as breast cancer [27, 28] and
cardiac transplantation [29, 30]. These clinical genetic tests
are being used in two different ways—generating detailed
disease characterization or establishing disease susceptibil-
ity. Current testing for breast cancer and cardiac transplan-
tation is used for more detailed disease characterization.
The tests are performed to generate a highly detailed
molecular phenotype of the disease-related tissue to further
stratify patients into clinical subgroups. For example, in
breast cancer, the traditional approach for categorizing a
subject, as either low or high risk for future disease
recurrence, is to use clinical factors such as tumor size,
lymph node status, and histological grade. The molecular
information generated from tumors by genetic testing can
be used to identify subgroups within the clinically
estimated low risk category who are actually at significantly
higher risk for disease recurrence and will have outcomes in
line with patients in the high risk category, thus, further
refining the diagnostic process. Such knowledge can have a
significant impact on clinical decision making with regard
to surgery and chemotherapy. In the case of cardiac
transplantation, the genetic tests can identify subtle changes
in the peripheral blood mononuclear cells that can be used
to detect organ rejection much earlier than traditional
histopathology. In the examples of breast cancer and
cardiac transplantation, the disease diagnosis has already
been established, and the genetic testing can be thought of
as an extension of currently available biochemical and
histopathological testing that aids in clinical decision
making or determining prognosis by the virtue of providing
more detailed molecular phenotype information. There are
no current genetic tests that meet these criteria with respect
to CHD.
The second way to apply genetic information is to
establish disease susceptibility by defining a person’s
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individual risk beyond currently available risk assessment
tools. There are a number of commercially available tests
that fall in this category including tests for susceptibility for
diabetes [31, 32], atrial fibrillation [33], and myocardial
infarction [17, 18]. The purpose of such genetic testing is to
identify individuals at higher risk who would, then, receive
more intensive preventive medical treatments in hopes of
delaying or preventing disease development. While this is
an intriguing opportunity, there are several issues to
consider about using this new generation of clinical genetic
testing [34, 35]. The first is in the interpretation of the
results. Unlike single gene disorders, the results of a
positive or negative test provide no concrete diagnostic or
prognostic information. A positive test simply means that a
patient has an elevated risk for developing the disorder—it
is not a near certainty. Similarly, a negative test does not
guarantee that the patient will not ultimately develop the
disease. The results of the genetic testing are not given in
the context of a subject’s current traditional risk factor
profile. That is to say, clinical and genomic information are
not integrated in the diagnostic testing process, and it is not
yet clear what additional prognostic information genetic
testing provides beyond risk assessments based on standard
clinical risk factor models. Another issue about the clinical
genetic testing for multigenic complex disorders is what
clinical interventions should be administered given the test
results. For example, if the genotyping indicates that the
individual is at risk for a future myocardial infarction,
should intensive medical therapies be prescribed? As
indicated above, a positive test only means that there is an
increased risk for having a myocardial infarction at some
future time. Intensive medical therapies such as blood
pressure reduction, augmented antiplatelet therapy, and
aggressive cholesterol lowering have all been shown to
substantially reduce CHD. While quite effective in reducing
risk and being relatively safe, universal administration of
these therapies is both financially infeasible and would lead
to unnecessary side effects. However, with the use of
genomic information, it may be possible to identify disease-
susceptible individuals for whom intensive prevention is
cost effective. It remains to be seen whether this hypothesis
will be borne out. Will the benefits of interventions applied
in response to a positive genomic test outweigh the risks of
unnecessary treatment and financial costs and result in
durable and cost effective improvements in health? On the
other hand, given that there is no guarantee of a disease-free
future, will a negative test lead to a false sense of security
and encourage the maintenance or resumption of prior
deleterious behaviors? Therefore, further evaluation of the
utility of these tests through carefully designed disease
outcome trials need to be performed. Finally, there are
potentially problematic legal and ethical issues surrounding
clinical genetic testing for complex diseases that go beyond
the scope of this review. While the results of the test
provide no concrete diagnostic or prognostic information,
they may have potentially significant effects on health
insurance premiums or employment.
Finally, another way to translate new genetic information
into clinical practice is through the identification of targets
for drug development or modified uses for currently
existing medications. While a straightforward idea, there
are still a few hurdles to overcome. The primary one is to
provide convincing evidence that a gene contributes to
disease development and progression. In the case of linkage
studies, sometimes, it is difficult to determine the dominant
candidate genes. Often, these studies identify chromosomal
regions associated with disease that are 10 cM or roughly
ten million nucleotides in length. A region of this size may
contain 100–300 potential genes making it challenging to
identify the causal gene(s). For whole genome association
studies, an associated SNP is not necessarily functionally
relevant and may simply be tightly linked with the real
unidentified causal gene. In some cases, the SNP may not
even lie within a known or putative gene. For candidate
genes identified by functional genomics studies, the
difficulty is determining whether the gene expression levels
are altered because the genes are contributing to disease
biology or whether the genes are altered as a consequence
of the disease process.
Conclusion
In the recent past, a significant effort was devoted toward
developing methods for generating robust genetic informa-
tion about complex disorders such as CHD. Technical
innovations are now enabling researchers to overcome the
challenges of dissecting multigenic diseases. The combina-
tion of advanced genomic technologies, reduced assay
costs, and the availability of large well-characterized study
cohorts provide researchers with the unprecedented oppor-
tunity to determine the genetic framework for multigenic
disorders such as CHD. There are a number of studies in
the literature that have used these technologies to generate
more detailed information about the genes that contribute to
the development and progression of coronary atherosclero-
sis and its thromboembolic complications such as myocar-
dial infarction. Knowledge of the genes that influence CHD
may ultimately lead to the development of novel treatments
and more effective diagnostic and prognostic tools. There
are commercially available genetic tests for to assess risk
for myocardial infarction currently on the market. However,
we must work on the next steps to understand how and
when to apply genetic information and study whether this
new generation of information will lead to true improve-
ments that are cost effective and improve the quality of
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health care. But what is certain is that technology is ever
improving its speed and accuracy in examining the entire
genome, pathways and protein products. Newer analytical
methods and tools are also being developed to handle such
complicated data and information, allowing for the integra-
tion of genetic data into the current knowledge of
cardiovascular disease. We have entered a new era of
genetic investigation.
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